Comparison of Iron Profile in Patients With and Without Coronary Heart Disease.
association
coronary artery disease
ferritin
iron
oxidized low density lipoprotein
serum iron level
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
accepted:
11
06
2021
entrez:
19
7
2021
pubmed:
20
7
2021
medline:
20
7
2021
Statut:
epublish
Résumé
Introduction Atherosclerosis is considered a major cause of coronary artery disease (CAD). Pathogenesis of atherosclerosis involves the oxidation of low-density lipoprotein (LDL) within the lysosomes of macrophages. Ferritin and iron have pro-oxidant properties, and ferritin is an independent positive determinant of oxidized LDL level. In this study, we will determine the association between ferritin and serum iron levels and CAD. Methods This case-control study was conducted in the cardiology unit of a tertiary care hospital in Pakistan from December 2020 to April 2021. After taking informed consent, 400 patients with a confirmed diagnosis of CAD were enrolled. Another set of 400 patients without a history of CAD were included in the control group. A blood sample of 5 ml was drawn and sent to the laboratory to test for ferritin, serum iron, and total iron-binding capacity (TIBC). Ferritin, serum iron, and iron-binding capacity were compared between the case and control groups. Results Serum ferritin was significantly higher in patients with CAD compared to patients without CAD (921.21 ± 201.21 ug/L vs. 101.21 ± 92.21 ug/L; p-value: <0.0001). Serum TIBC was significantly lower in patients with CAD compared to patients without CAD (302.12 ± 101.75 umol/L vs. 362.12 ± 82.16 umol/L). Conclusion Patients with raised levels of ferritin should consult a physician to manage their ferritin levels since they are at a greater risk of CAD. Treatment ranges from lifestyle changes to pharmacological therapy, thus reducing the overall risk and normalizing the ferritin levels.
Identifiants
pubmed: 34277231
doi: 10.7759/cureus.15613
pmc: PMC8275058
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e15613Informations de copyright
Copyright © 2021, Amar et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Am J Med Sci. 2011 Aug;342(2):135-42
pubmed: 21747278
Atherosclerosis. 2015 Feb;238(2):296-303
pubmed: 25544180
Curr Atheroscler Rep. 2013 Oct;15(10):358
pubmed: 24057693
Indian Heart J. 2012 Mar-Apr;64(2):173-7
pubmed: 22572495
J Res Health Sci. 2015 Summer;15(3):147-51
pubmed: 26411659
Endocr J. 2006 Oct;53(5):665-70
pubmed: 16902260
Br J Haematol. 2018 May;181(3):331-340
pubmed: 29672840
Biochemistry. 2012 May 8;51(18):3767-75
pubmed: 22493939
J Pak Med Assoc. 2017 Nov;67(11):1723-1729
pubmed: 29171568
Diabetes Care. 2012 Dec;35(12):2521-6
pubmed: 22933431
J Cardiovasc Thorac Res. 2012;4(1):1-4
pubmed: 24250972
Clin Chem. 2001 Sep;47(9):1666-72
pubmed: 11514401
Ann N Y Acad Sci. 2001 Dec;947:199-205; discussion 205-6
pubmed: 11795267
Atherosclerosis. 2020 Jan;293:69-74
pubmed: 31865056
ARYA Atheroscler. 2014 Jan;10(1):32-6
pubmed: 24963311